Karyopharm Therapeutics Inc. (KPTI)
NASDAQ: KPTI · Real-Time Price · USD
10.21
+0.75 (7.93%)
At close: Jun 26, 2026, 4:00 PM EDT
10.18
-0.03 (-0.29%)
After-hours: Jun 26, 2026, 7:42 PM EDT
Karyopharm Therapeutics Stock Forecast
Stock Price Forecast
The 6 analysts with 12-month price forecasts for Karyopharm Therapeutics stock have an average target of 15.83, with a low estimate of 7.00 and a high estimate of 28. The average target predicts an increase of 55.04% from the current stock price of 10.21.
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for Karyopharm Therapeutics stock from 7 stock analysts is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Jan '26 | Feb '26 | Mar '26 | Apr '26 | May '26 | Jun '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 3 | 4 | 4 | 4 | 4 | 4 |
| Buy | 2 | 2 | 2 | 2 | 2 | 2 |
| Hold | 1 | 1 | 1 | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 6 | 7 | 7 | 7 | 7 | 7 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| H.C. Wainwright | H.C. Wainwright | Buy Reiterates $13 | Buy | Reiterates | $13 | +27.33% | Jun 17, 2026 |
Unknown Analyst Leerink Partners No rating | Leerink Partners | Hold Reiterates $5 → $7 | Hold | Reiterates | $5 → $7 | -31.44% | May 15, 2026 |
| RBC Capital | RBC Capital | Buy Maintains $16 | Buy | Maintains | $16 | +56.71% | May 15, 2026 |
| Piper Sandler | Piper Sandler | Buy Reiterates $8 → $16 | Buy | Reiterates | $8 → $16 | +56.71% | Apr 27, 2026 |
| Robert W. Baird | Robert W. Baird | Buy Maintains $21 → $15 | Buy | Maintains | $21 → $15 | +46.91% | Mar 25, 2026 |
Financial Forecast
Revenue This Year
137.21M
from 146.07M
Decreased by -6.06%
Revenue Next Year
155.30M
from 137.21M
Increased by 13.18%
EPS This Year
-4.95
from -12.22
EPS Next Year
-4.89
from -4.95
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | 157.8M | 191.5M | |
| Avg | 137.2M | 155.3M | |
| Low | 123.8M | 120.9M |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | 8.0% | 39.6% | |
| Avg | -6.1% | 13.2% | |
| Low | -15.2% | -11.9% |
EPS Forecast
| EPS | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | -3.58 | -3.21 | |
| Avg | -4.95 | -4.89 | |
| Low | -6.03 | -6.57 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | - | - | |
| Avg | - | - | |
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.